PHS
ITCI icon

PFM Health Sciences’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

PFM Health Sciences’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-40,610
Closed -$3.39M – 96
2024
Q4 		$3.39M Sell
40,610
-36,777
-48% -$3.02M 0.21% 61
2024
Q3 		$5.66M Sell
77,387
-93,013
-55% -$6.99M 0.32% 50
2024
Q2 		$11.7M Buy
170,400
+71,521
+72% +$4.96M 0.58% 45
2024
Q1 		$6.84M Buy
+98,879
New +$6.8M 0.32% 61

Other funds holding ITCI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Pentwater Capital Management
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
HBK Investments
HBK Investments Dallas, Texas $10.3B AUM 67.69% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Davidson Kempner Capital Management
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
UBS O'Connor
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

PFM Health Sciences's ITCI Position: Q1 2025 in Review

PFM Health Sciences sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 40,610 shares — an estimated $3.39M sold.

PFM Health Sciences first reported a position in ITCI in Q1 2024 and held it in 4 quarters. The position peaked at $11.7M in Q2 2024. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

  • PFM Health Sciences reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
  • PFM Health Sciences sold 40,610 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $3.39M.
  • PFM Health Sciences first reported a position in Intra-Cellular Therapies Inc. in Q1 2024 and held it in 4 quarters.
  • PFM Health Sciences's Intra-Cellular Therapies Inc. position peaked at $11.7M in Q2 2024.
  • 395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on PFM Health Sciences's 13F filing for Q1 2025, filed 15 May 2025.